Fig. 3

Differential expression of TCIRG1 in renal tumor tissue and normal renal tissue and Kaplan-Meier survival analysis of Overall survival(OS)and Progression Free Interval (PFI) in KIRC patients. (A) The TIMER 2.0 Gene_DE module was used to detected the difference in TCIRG1 mRNA expression between tumor tissues and adjacent normal tissues in TCGA cancer types. The distribution of gene expression levels is shown in a box plot. The result of the KIRC dataset is marked with a red box. (B-C) UALCAN analysis showed that in the KIRC dataset of TCGA, the differential expression of TCIRG1 mRNA in primary tumor tissue and adjacent normal tissue was analyzed; In the ccRCC dataset of CPTAC, there is a difference in the expression of TCIRG1 protein between primary tumor tissue and adjacent normal tissue. (D-F) UALCAN analysis showed that in the KIRC dataset, there were differences in the expression of TCIRG1 at different tumor differentiation levels (D), lymph node metastasis (E), and different tumor stages (F). Tumor differentiation levels are defined as: Grade 1, well-differentiated; Grade 2, moderately differentiated; Grade 3, poorly differentiated; Grade 4, undifferentiated. There are differences in the expression of undifferentiated tumor differentiation level (E) and lymph node metastasis (F). (G-L) K-M survival curve analysis showed that in the training cohort (n = 262; G, I), validation cohort (n = 263; H, J), and combined cohort (n = 525; K, L), KIRC patients with high TCIRG1 expression had short OS and PFI. (all p values were defined as *p < 0.05, **p < 0.01 and ***p < 0.001, log rank test). KIRC, Kidney Renal Carcinoma; mRNA, messenger RNA; UALCAN, The University of ALabama at Birmingham Cancer data analysis Portal; CPTAC, Clinical Proteomic Tumor Analysis Consortium